Auriacombe, M, Fatseas, M, Dubernet, J et al (2004) French field experience with buprenorphine. American Journal on Addictions; 13: S17–28.
Blackwell, J (1988) The saboteurs of Britain's opiate policy: over-prescribing physicians or American-style ‘junkies’?
International Journal of Addiction; 23: 517–26.
British Medical Association, Royal Pharmaceutical Society of Great Britain (2008) British National Formulary 55. Pharmaceutical Press.
Chua, SM, Lee, TS (2006) Abuse of prescription buprenorphine, regulatory controls and the role of the primary physician. Annals of Academic Medicine Singapore; 35: 492–5.
Ciccocioppo, R, Economidou, D, Rimondini, R et al (2007) Buprenorphine reduces alcohol drinking through activation of the nociceptin/orphanin FQ-NOP receptor system. Biological Psychiatry; 61: 4–12.
Clark, NC, Lintzeris, N, Muhleisen, PJ (2002) Severe opiate withdrawal in a heroin user precipitated by a massive buprenorphine dose. Medical Journal of Australia; 176: 167–8.
Coffin, PO, Blaney, S, Fuller, C et al (2006) Support for buprenorphine and methadone prescription to heroin-dependent patients among New York City physicians. American Journal of Drug and Alcohol Abuse; 32: 1–6.
Comer, SD, Collins, ED, Fischman, MD (2001) Buprenorphine sublingual tablets: effects on IV heroin self-administration by humans. Psychopharmacology; 154: 28–37.
Comer, SD, Collins, ED (2002) Self-administration of intravenous buprenorphine and the buprenorphine/naloxone combination by recently detoxified heroin abusers. Journal of Pharmacology and Experimental Therapeutics; 303: 695–703.
Comer, SD, Sullivan, MA, Walker, EA (2005) Comparison of intravenous buprenorphine and methadone self-administration by recently detoxified heroin-dependent individuals. Journal of Pharmacology and Experimental Therapeutics; 315: 1320–30.
Comer, SD, Sullivan, MA, Whittington, RA et al (2007) Abuse liability of prescription opioids compared to heroin in morphine-maintained heroin abusers. Neuropsychopharmacology; 1: 1–13.
Cunningham, CO, Sohler, NL, McCoy, K et al (2006) Attending physicians' and residents' attitudes and beliefs about prescribing buprenorphine at an urban teaching hospital. Family Medicine; 38: 336–40.
Department of Health (1999) Drug Misuse and Dependence. Guidelines on Clinical Management. HMSO.
De Wet, CJ, Reed, LJ, Bearn, J (2005) The rise of buprenorphine prescribing in England: analysis of NHS regional data, 2001–03. Addiction
Doran, CM, Shanahan, M, Mattick, RP et al (2003) Buprenorphine versus methadone maintenance: a cost-effectiveness analysis. Drug and Alcohol Dependence; 71: 295–302.
Dum, J, Bläsig, J, Herz, A (1981) Buprenorphine: demonstration of physical dependence liability. European Journal of Pharmacology; 70: 293–300.
Elkader, A, Sproule, B (2005) Buprenorphine. Clinical pharmacokinetics in the treatment of opioid dependence. Clinical Pharmacokinetics; 44: 661–80.
Gowing, L, Ali, R, White, J (2004) Buprenorphine for the management of opioid withdrawal. Cochrane Database of Systematic Reviews; issue 4: CD002025.
Gunderson, EW, Fiellin, DA, Levin, FR et al (2006) Evaluation of combined online and in person training in the use of buprenorphine. Substance Abuse; 27: 39–45.
Handelsman, L, Cochrane, KJ, Aronson, MJ et al (1987) Two new rating scales for opiate withdrawal. American Journal of Alcohol Abuse; 13: 293–308.
Ho, RC, Ho, EC, Mak, A (2009) Cutaneous complications among i.v. buprenorphine users. Journal of Dermatology; 36: 22–9.
Houde, RW (1979) Analgesic effectiveness of the narcotic agonist-antagonists. British Journal of Clinical Pharmacology; 7: 2975–3085.
Hulse, G, White, J, Cape, G (2002) Management of Alcohol and Drug Problems. Oxford University Press.
International Centre for Drug Policy (2007) Drug-Related Deaths in the UK. Annual Report. St George's Hospital, University of London.
Jasinski, DR, Fudala, PJ, Johnson, RE (1989) Sublingual versus subcutaneous buprenorphine on opiate abusers. Clinical Pharmacology and Therapeutics; 45: 513–9.
Jenkinson, RA, Clark, NC, Fry, CL et al (2005) Buprenorphine diversion and injection in Melbourne, Australia: an emerging issue?
Addiction; 100: 197–205.
Kakko, J, Grönbladh, L, Svanborg, KD et al (2007) A stepped care strategy using buprenorphine and methadone versus conventional methadone maintenance in heroin dependence: a randomised controlled trial. American Journal of Psychiatry; 164: 797–803.
Kintz, P (2001) Deaths involving buprenorphine: a compendium of French cases. Forensic Science International; 121: 65–9.
Lapeyre-Mestre, M, Llau, ME, Gony, M et al (2003) Opiate maintenance with buprenorphine in ambulatory care: a 24-week follow-up study of new users. Drug and Alcohol Dependence; 72: 297–303.
Lewis, JW (1985) Buprenorphine. Drug and Alcohol Dependence; 14: 363–72.
Lingford-Hughes, AR, Welch, S, Nutt, DJ (2004) Evidence-based guidelines for the pharmacological management of substance misuse, addiction and comorbidity: recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology; 18: 293–335.
Lintzeris, N, Ritter, A, Dunlop, A (2002) Training primary health care professionals to provide buprenorphine and LAAM treatment. Substance Abuse; 23: 245–54.
Luty, J, O'Gara, C, Sessay, M (2005) Is methadone too dangerous for opiate addiction? The case for using a safer alternative, buprenorphine is strong. BMJ; 331: 1352–3.
Magura, S, Lee, SJ, Salsitz, EA et al (2007) Outcomes of buprenorphine maintenance in office-based practice. Journal of Addiction Disorder; 26: 13–23.
Marlatt, GA, Gordon, JR (1985) Relapse Prevention: A Self-Control Strategy for the Maintenance of Behaviour Change. Guilford Press.
Mattick, RP, Kimber, J, Breen, C et al (2002) Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database of Systematic Reviews; issue 4: CD002209.
Macleod, J, Whittaker, A, Robertson, JR (1998) Changes in opiate treatment during attendance at a community drug service – findings from a clinical audit. Drug and Alcohol Review; 17: 19–25.
McIntosh, C, Ritson, B (2001) Treating depression complicated by substance misuse. Advances in Psychiatric Treatment; 7: 357–64.
O'Connor, J, Moloney, E, Travers, R et al (1988) Buprenorphine abuse among opiate addicts. British Journal of Addiction; 83: 1085–7.
Pradel, V, Thirion, X, Ronfle, E et al (2003) Assessment of doctor-shopping for high dosage buprenorphine maintenance treatment in a French region: development of a new method for prescription database. Pharmacoepidemiology and Drug Safety; 13: 473–81.
Raisch, DW, Fudala, PJ, Saxon, AJ et al (2003) Pharmacists' and technicians' perceptions and attitudes toward dispensing buprenorphine/naloxone to patients with opioid dependence. Journal of American Pharmacology Association; 45: 23–32.
Robertson, JR, Raab, GM, Bruce, M et al (2006) Addressing the efficacy of dihydrocodeine versus methadone as an alternative maintenance treatment for opiate dependence: a randomized controlled trial. Addiction; 101: 1752–9.
Rosenheck, R, Kosten, T (2001) Buprenorphine for opiate addiction: potential economic impact. Drug and Alcohol Dependence; 63: 253–62.
Schifano, F, Corkery, J, Gilvan, E et al (2005) Buprenorphine mortality, seizures and prescription data in the UK, 1980–2002. Human Psychopharmacological Clinical Experiments; 20: 343–8.
Strang, J, Sheridan, J, Hunt, C et al (2005) The prescribing of methadone and other opioids to addicts: national survey of GPs in England and Wales. British Journal of General Practitioners; 55: 444–51.
Strang, J, Manning, V, Mayet, S et al (2007) Does prescribing for opiate addiction change after national guidelines? Methadone and buprenorphine prescribing to opiate addicts by general practitioners and hospital doctors in England, 1995–2005. Addiction; 102: 761–70.
Taikato, M, Kidd, B, Baldacchino, A (2005) What every psychiatrist should know about buprenorphine in substance misuse. Psychiatric Bulletin; 29: 225–7.
Tracqui, A, Kintz, P, Ludes, B (1998) Buprenorphine-related deaths among drug addicts in France: a report on 20 fatalities. Journal of Annalytical Toxicology; 22: 430–4.
Walsh, SL, Preston, KL, Stitzer, ML et al (1994) Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clinical Pharmacology Therapy; 55: 569–80.
Winstock, AR, Lea, T, Ritter, A (2007) The impact of community pharmacy dispensing fees on the introduction of buprenorphine-naloxone in Australia. Drug and Alcohol Review; 26: 411–6.
Yanagita, T, Kato, S, Wakasa, Y et al (1982) Dependence potential of buprenorphine studied in rhesus monkeys. In Problems of Drug Dependence, 1981. National Institute on Drug Abuse Research Monograph 41) (ed Harris, LS) 208–14. US Government Printing Office.
Zacny, JP, Conley, K, Galinkin, J (1997) Comparing the subjective, psychomotor and physiological effects of intravenous buprenorphine and morphine in healthy volunteers. Journal of Pharmacology and Experimental Therapeutics; 282: 1187–97.